Approvals/TGA/PAVTIDE MDI 125/25 fluticasone propionate 125 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)

Approved

STANDARD

PAVTIDE MDI 125/25 fluticasone propionate 125 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)

GlaxoSmithKline Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 30, 2025
Approval ID: 35c584597e42fd5a
Company: GlaxoSmithKline Australia Pty Ltd
Type: Standard

Approval Details

Approval Id: 35c584597e42fd5a
Product Name: PAVTIDE MDI 125/25 fluticasone propionate 125 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)
Artg Id: 208670
Artg Name: PAVTIDE MDI 125/25 fluticasone propionate 125 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)
Sponsor: GlaxoSmithKline Australia Pty Ltd
Company Detail Path: /organization/glaxosmithkline-australia-pty-ltd
Artg Date: 2014-05-07
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/072cc3e1829c5a36a1c26a4444a33cdd.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/42d2a50d04b7da123e45c2f8f98453fb.pdf

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

35c584597e42fd5a

Type

Standard

Back to TGA Approvals